The definition and measurement of disease modification in inflammatory rheumatic diseases

被引：126
作者：
Aletaha, D
Smolen, JS
机构：
[1] Univ Vienna, Dept Rheumatol, A-1090 Vienna, Austria
[2] NIAMSD, NIH, Bethesda, MD 20892 USA
[3] Lainz Hosp, Dept Med 2, Vienna, Austria
来源：
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA | 2006年 / 32卷 / 01期
关键词：
D O I：
10.1016/j.rdc.2005.09.005
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
This article focuses on measures that are used to evaluate disease activity, damage, and function in three major inflammatory musculoskeletal disorders. The instruments used in rheumatoid arthritis, where most of the methodologic work has been done, are extensively discussed and instruments for the respective domains in psoriatic arthritis and ankylosing spondylitis are likewise presented.
引用
收藏
页码：9 / +
页数：37
相关论文
共 203 条
[1]  
ABBOTT CA, 1994, BRIT J RHEUMATOL, V33, P1060
[2]   The American College of Rheumatology N (ACR-N) debate: going back into the middle of the tunnel? Comment on the articles by Siegel and Zhen and by Boers [J].
Aletaha, D ;
Smolen, JS .
ARTHRITIS AND RHEUMATISM, 2006, 54 (01) :377-378
[3]  
Aletaha D, 2004, ANN RHEUM DIS, V63, P111
[4]   Remission and active disease in rheumatoid arthritis - Defining criteria for disease activity states [J].
Aletaha, D ;
Ward, MM ;
Machold, KP ;
Nell, VPK ;
Stamm, T ;
Smolen, JS .
ARTHRITIS AND RHEUMATISM, 2005, 52 (09) :2625-2636
[5]   Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score [J].
Aletaha, D ;
Nell, VP ;
Stamm, T ;
Uffmann, M ;
Pflugbeil, S ;
Machold, K ;
Smolen, JS .
ARTHRITIS RESEARCH & THERAPY, 2005, 7 (04) :R796-R806
[6]  
ALETAHA D, 2005, ARTHRITIS RHEUM S, V52
[7]  
ALETAHA D, 2005, IN PRESS ANN RHEUM D
[8]  
Anderson JJ, 2001, ARTHRITIS RHEUM-US, V44, P1876, DOI 10.1002/1529-0131(200108)44:8<1876::AID-ART326>3.0.CO
[9]  
2-F
[10]   Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis - Results from the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT) [J].
Antoni, CE ;
Kavanagh, A ;
Kirkham, B ;
Tutuncu, Z ;
Burmester, GR ;
Schneider, U ;
Furst, DE ;
Molitor, J ;
Keystone, E ;
Gladman, D ;
Manger, B ;
Wassenberg, S ;
Weier, R ;
Wallace, DJ ;
Weisman, MH ;
Kalden, JR ;
Smolen, J .
ARTHRITIS AND RHEUMATISM, 2005, 52 (04) :1227-1236
12345678910